Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients
Growing evidence suggests that the patient’s immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunotherapy (R...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/875343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850209513709240320 |
|---|---|
| author | Franz Buchegger Steven M. Larson Jean-Pierre Mach Yves Chalandon Pierre-Yves Dietrich Anne Cairoli John O. Prior Pedro Romero Daniel E. Speiser |
| author_facet | Franz Buchegger Steven M. Larson Jean-Pierre Mach Yves Chalandon Pierre-Yves Dietrich Anne Cairoli John O. Prior Pedro Romero Daniel E. Speiser |
| author_sort | Franz Buchegger |
| collection | DOAJ |
| description | Growing evidence suggests that the patient’s immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunotherapy (RIT). Rituximab maintenance, furthermore, has a major efficacy in prolonging recurrence free survival after chemotherapy. On the other hand, RIT as a single step treatment showed a remarkable capacity to induce complete and partial remissions when applied in recurrence and as initial treatment of FL or given for consolidation. These clinical results strongly suggest that RIT combined with rituximab maintenance could stabilize the high percentages of patients with CR and PR induced by RIT. While the precise mechanisms of the long-term efficacy of these 2 treatments are not elucidated, different observations suggest that the patient’s T cell immune response could be decisive. With this review, we discuss the potential role of the patient’s immune system under rituximab and RIT and argue that the T cell immunity might be particularly promoted when combining the 2 antibody treatments in the early therapy of FL. |
| format | Article |
| id | doaj-art-983ddd5e1d944c3eaa0aa149e5748b51 |
| institution | OA Journals |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-983ddd5e1d944c3eaa0aa149e5748b512025-08-20T02:09:59ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/875343875343Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma PatientsFranz Buchegger0Steven M. Larson1Jean-Pierre Mach2Yves Chalandon3Pierre-Yves Dietrich4Anne Cairoli5John O. Prior6Pedro Romero7Daniel E. Speiser8Department of Nuclear Medicine, Lausanne University Hospital, 1011 Lausanne, SwitzerlandDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Biochemistry, University of Lausanne, 1066 Lausanne, SwitzerlandDepartment of Hematology, Geneva University Hospitals, 1211 Geneva, SwitzerlandDepartment of Oncology, Geneva University Hospitals, 1211 Geneva, SwitzerlandDepartment of Oncology, Lausanne University Hospital, 1011 Lausanne, SwitzerlandDepartment of Nuclear Medicine, Lausanne University Hospital, 1011 Lausanne, SwitzerlandLudwig Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, SwitzerlandLudwig Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, SwitzerlandGrowing evidence suggests that the patient’s immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunotherapy (RIT). Rituximab maintenance, furthermore, has a major efficacy in prolonging recurrence free survival after chemotherapy. On the other hand, RIT as a single step treatment showed a remarkable capacity to induce complete and partial remissions when applied in recurrence and as initial treatment of FL or given for consolidation. These clinical results strongly suggest that RIT combined with rituximab maintenance could stabilize the high percentages of patients with CR and PR induced by RIT. While the precise mechanisms of the long-term efficacy of these 2 treatments are not elucidated, different observations suggest that the patient’s T cell immune response could be decisive. With this review, we discuss the potential role of the patient’s immune system under rituximab and RIT and argue that the T cell immunity might be particularly promoted when combining the 2 antibody treatments in the early therapy of FL.http://dx.doi.org/10.1155/2013/875343 |
| spellingShingle | Franz Buchegger Steven M. Larson Jean-Pierre Mach Yves Chalandon Pierre-Yves Dietrich Anne Cairoli John O. Prior Pedro Romero Daniel E. Speiser Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients Clinical and Developmental Immunology |
| title | Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients |
| title_full | Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients |
| title_fullStr | Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients |
| title_full_unstemmed | Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients |
| title_short | Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients |
| title_sort | radioimmunotherapy combined with maintenance anti cd20 antibody may trigger long term protective t cell immunity in follicular lymphoma patients |
| url | http://dx.doi.org/10.1155/2013/875343 |
| work_keys_str_mv | AT franzbuchegger radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT stevenmlarson radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT jeanpierremach radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT yveschalandon radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT pierreyvesdietrich radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT annecairoli radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT johnoprior radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT pedroromero radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients AT danielespeiser radioimmunotherapycombinedwithmaintenanceanticd20antibodymaytriggerlongtermprotectivetcellimmunityinfollicularlymphomapatients |